bioMérieux’s business review for the year ended December 31, 2014

22 January, 2015

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2014.

Sales: solid growth, lifted sharply by BioFire

  • Revenue: €1,698 million, up a reported 7%
  • Up 8.7%, including BioFire and at constant exchange rates
  • Up 3.8% at constant exchange rates and scope of consolidation, in line with the full-year target

Operations: significant headway

  • BioFire
  • Fast 60% growth in sales, led by the respiratory panel
  • Preparations underway to launch the higher-throughput FilmArray® 2.0 system
  • Production conditions at the Durham site restored

Strategy: major milestones reached during the quarter

  • Automated clinical microbiology: strategic partnership with Copan
  • Next Generation Sequencing: collaboration with Illumina
  • High medical value assays: agreement with Astute Medical
  • Food-related molecular virology tests: acquisition of CEERAM

Organic growth in sales expected to accelerate in 2015

“In 2014, bioMérieux stepped up implementation of its strategic plan, in particular with the acquisition of BioFire in molecular biology, and redeployed its operational organization,” said Chairman Jean-Luc Belingard. “With outcomes in line with the objectives set early in the year, I am especially pleased with the progress made by our Company under the leadership of our new Management Committee, headed by Chief Executive Officer Alexandre Mérieux."

From the CEO:

“Today, bioMérieux announced sales growth at constant exchange rates of nearly 9% and of 3.8% at constant scope of consolidation,” said Chief Executive Officer Alexandre Mérieux. “Our sales performance was in line with the target set early in the year, reflecting our competitiveness and ability to adjust to changing market conditions. In addition, with the signature of eight business development agreements in 2014, we reached decisive milestones in the deployment of our roadmap. This robust strategic and operational dynamic, combined with our solid fundamentals, sustained favorable momentum in North America and expanding product portfolio, especially in molecular biology and automated microbiology, enables us to expect sales to accelerate in 2015, and growth of between 4.5% and 6.5% at constant exchange rates and scope of consolidation.”

Download the Full Report:

Download
Pioneering Diagnostics